Biotech Values

[DewDiligence]

ASMB axes ABI-H0731 program:

https://finance.yahoo.com/news/assembly-biosciences-updates-pipeline-strategy-210000963.html

Assembly Biosciences…today announced that it is foregoing its plans to initiate Phase 3 registrational studies of vebicorvir (VBR, or ABI-H0731) as a chronic suppressive therapy (CST) to concentrate its research and development efforts on finite and curative HBV therapies.

As part of this focused strategy on finite and curative HBV therapies, Assembly Bio will prioritize its portfolio of potent next generation core inhibitors and combinations of VBR with complementary mechanisms of action, and plans to rapidly advance multiple research programs focused on novel targets and new mechanisms to the clinic.

The company evidently agrees with my take on the program spelled out in #msg-159346890.

Please see #msg-159327881 for additional background info.